Skip to main content

Clinical trial ARTEMIDE-01

A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non small Cell Lung Cancer (ARTEMIDE-01)(D7020C00001)

Organ Lung
Trial status Trial open for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 1/2
Academic trial Non
Sponsor AstraZeneca
EudraCT Identifier 2021-000857-23
Last update